NanoViricides, Inc. NNVC

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
24/100
Weak

About NanoViricides, Inc.

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections … Full NNVC analysis →

Competitive advantage assessment

Key risks

  • Elevated Debt Risk Debt serviceability is weak (score 0.01), raising refinancing risk.
  • Weak or Negative Cash Flow Cash generation is weak (score 0.00), limiting financial flexibility.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Insufficient Data
—

Where NNVC ranks in Biotechnology

NanoViricides, Inc. ranks #574 of 713 scored companies in Biotechnology by moat score — the top 81%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

Moat scores for companies ranked near NNVC in Biotechnology
# Company Moat score Rating
570 Cocrystal Pharma, Inc. COCP 25/100 Weak
571 Achieve Life Sciences, Inc. ACHV 24/100 Weak
572 Skye Bioscience, Inc. SKYE 24/100 Weak
573 Summit Therapeutics Inc. SMMT 24/100 Weak
574 NanoViricides, Inc. NNVC 24/100 Weak
575 NKGen Biotech, Inc. NKGN 24/100 Weak
576 Allogene Therapeutics, Inc. ALLO 24/100 Weak
577 NKGen Biotech, Inc. Warrants NKGNW 24/100 Weak
578 Kodiak Sciences Inc KOD 24/100 Weak

See every Biotech / Pre-Revenue company ranked by moat score →

How NNVC scores on the Corporate Default defenses

Pricing Power

Not measurable · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Not measurable · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Not measurable · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 32 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 13 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Not measurable · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding NNVC's moat

What is NanoViricides, Inc.'s moat score?

NanoViricides, Inc. (NNVC) scores 24 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as weak. It ranks #574 of 713 scored companies in Biotechnology, the top 81%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Capital Efficiency (32/100) and its weakest is Resilience (13/100).

How does NanoViricides, Inc. compare with other Biotechnology companies?

NanoViricides, Inc. ranks #574 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Summit Therapeutics Inc. (SMMT) at 24 just above it and NKGen Biotech, Inc. (NKGN) at 24 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is NanoViricides, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for NanoViricides, Inc.?

The Corporate Default template measures 6 defenses, and NNVC scores: Pricing Power (not measurable), Cost Advantage (not measurable), Customer Stickiness (not measurable), Capital Efficiency (32), Resilience (13), Scale & Market Position (not measurable). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000